JAK1 and SAPHO syndrome: Janus kinase (JAK) inhibitors have emerged as a potential alternative, but data on the selective JAK1 inhibitor upadacitinib in SAPHO syndrome are lacking.<h4>Case summary</h4>An 18-year-old male presented with a 7-year history of recurrent facial acne since 2016.